Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

American Research Corporation

Neither a doctor nor a teaching hospital

Research payments

$32,837,118

1,298 payments

Through program year 2025, American Research Corporation is reported as receiving $32,837,118 in research payments, across 1,298 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,757,579 335
2024 Research $5,477,186 242
2023 Research $7,110,729 171
2022 Research $2,108,706 195
2021 Research $2,625,791 104
2020 Research $3,754,605 104
2019 Research $5,002,522 147

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $10,745,542 32 payments
  2. AstraZeneca UK Limited $5,449,792 27 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $2,224,378 25 payments
  4. Intercept Pharmaceuticals, Inc. $2,113,871 232 payments
  5. Amgen Inc. $1,627,705 2 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $1,435,209 121 payments
  7. Celgene Corporation $1,401,673 17 payments
  8. CTI BioPharma Corp. $1,172,656 11 payments
  9. Ipsen Bioscience Inc $1,067,675 205 payments
  10. Bausch Health US, LLC $773,501 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled, 2-Part, Parallel Group, Multiple Dose Phase 2 Study To Evaluate The Efficacy and Safety of BMS-986263 In Adults With Advanced Hepatic Fibrosis From Hepatitis C Who Have Achieved Sustained Virologic Response $2,142,867 1 payment
  2. An Open-Label Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants with Varying Degrees of Hepatic Impairment $1,622,855 1 payment
  3. Phase IIB in NASH mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH) $1,525,580 3 payments
  4. An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants with Non-alcoholic Fatty Liver Disease $1,511,073 3 payments
  5. A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment $1,341,012 4 payments
  6. A Phase 1, Open Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pacritinib in Subjects with Varying Degrees Hepatic Impairment Compared to Healthy Subjects $1,172,656 11 payments
  7. Phase I Single Dose,Non Randomised,Ope NLabel,Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics,Safety and Tolerability of Mitiperstat $1,001,551 3 payments
  8. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis $927,275 3 payments
  9. A Phase 1, Single-Arm, Open-Label, Multiple-Dose Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion Formulation in Adults Subjects with Impaired Hepatic Function and Healthy Matched Subjects as Controls $718,401 7 payments
  10. POCC in NASH $713,578 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record